News
FDA extends PDUFA date for review of Ryplazim , for the treatment of congenital plasminogen deficiency.- Liminal Biosciences
Liminal BioSciences Inc. a clinical-stage biopharmaceutical company, announced that the FDA has notified the Company that it has extended the review period for the Biologics License Application ("BLA") for Ryplazim (plasminogen), or Ryplazim, for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency.
The new Prescription Drug User Fee Act (PDUFA) target action date has been extended by the FDA by three months to June 5, 2021.
Condition: Plasminogen Congenital Deficiency.
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins